Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
about
Drug-resistant tuberculosis in Eastern Europe: challenges and ways forwardAmbulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agendaEarly outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern AfricaOutcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalenceAdverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, IndiaWhat is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patientsDrug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South AfricaDiagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.Global financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatmentCost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort StudyDrug-resistant tuberculosis in the WHO Western Pacific RegionAdverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia.Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-upRandomized trials to optimize treatment of multidrug-resistant tuberculosis.Epidemiology and treatment of multidrug resistant tuberculosisProtein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic reviewPhotoinactivation of Mycobacteria in vitro and in a new murine model of localized Mycobacterium bovis BCG-induced granulomatous infectionOutcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.Multidrug-resistant tuberculosis management in resource-limited settingsTime to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.TSH-CHECK-1 test: diagnostic accuracy and potential application to initiating treatment for hypothyroidism in patients on anti-tuberculosis drugs.Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam.Mycobacterium tuberculosis Complex Genotype Diversity and Drug Resistance Profiles in a Pediatric Population in Mexico.The burden of adverse events during treatment of drug-resistant tuberculosis in NamibiaOutcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan.Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.Preventing nosocomial MDR TB transmission in sub Saharan Africa: where are we at?Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.Prevalence of hypothyroidism among MDR-TB patients in BotswanaComprehensive treatment of extensively drug-resistant tuberculosis.Principles for designing future regimens for multidrug-resistant tuberculosis.Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.[Proposal of anti-tuberculosis regimens based on susceptibility to isoniazid and rifampicin].First use of bedaquiline in a patient with XDR-TB in Singapore.Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis.The Philippines case study.
P2860
Q26782448-887C3DEE-89D8-4E1B-9F15-494AD6B865ACQ28472337-76FD86C9-E6E1-4B79-BCA6-36D5D2A645F6Q28473126-5227664A-AC98-4DB7-96B9-836AA610CE80Q28476241-D6CCCA9C-7218-42D6-B764-50C193F1119EQ28479241-9B6AAF47-DA4D-45E6-A0E7-03AA04709A60Q28481249-09B78C4C-13D4-4CBB-BBE6-B122017FFE92Q28485194-4A5F62C7-A9E8-4885-83AF-8A673782B3E6Q28485930-BA8F1FC3-CDF4-4A5A-BDE9-C25E138AFB98Q28487731-AA420EF4-3DC0-4028-AF6B-FB77CB99DD99Q28487970-31B9B2DE-F359-4E80-AD12-DECA9A639B4EQ28543392-E9116D3C-4701-46C1-8538-93234A30803FQ28547335-F8D4C19B-9104-4CA5-81C2-AD58EDCB52B7Q28650417-5384AB09-D883-427F-A2D0-FFAFE7542539Q30829979-AF890866-C9AC-417E-9274-231B2D9A05CAQ30838132-6DCECC2F-1416-4F8F-B166-8F9DA80C50C9Q33305269-B476690E-24C7-4129-A131-4F5E274B1CD7Q33710690-30697410-B9CB-4BF3-B13C-CF919B58E0A4Q34237349-7676B662-68BF-4BAC-93C6-5E914CC00DC5Q34524569-17F5EDA0-5E67-483F-85CE-831A55571807Q34648536-E03E61A3-1B3B-4931-B228-9956563D7F35Q35062842-CE46D84C-F021-4260-BF11-69F54B96DE36Q35805726-FD12167F-4827-4200-845E-204F39F3B5F7Q35837236-DF2FDFFA-6106-41BF-BF10-534C18936832Q35839926-3E2FC315-ECE6-4FD7-B0A0-1330D707D848Q35875992-79FD17B5-93F3-474B-9312-08B8B459CD6EQ35910338-22824AD9-4ECA-406A-AFE6-65FA57F59203Q36317060-38B0A642-0A96-4AFA-AF30-4D7CBC96E3A4Q36420040-ACFA3B25-824B-4C37-A338-E5DEB80AA1A7Q36448646-B97FEB22-DBED-4164-A69C-598F1695F2FCQ36567190-C553830C-2F58-44E5-B606-E6096EB995B0Q36647864-879E0BD9-7F3F-447E-955E-9D698F49B986Q36809098-7606A8F4-10D6-4D8D-95EC-2C1EC007BF7DQ37061228-EC7EF2D6-FA93-415C-9568-62C62D454A0BQ37170546-9765CCDF-2FFC-4A43-8657-7BA168B73680Q37398037-D673D1EA-FF65-4EDD-AA2D-2472EF91D78BQ37589430-9AE5A4BF-D494-4150-83A4-9FC512CE74A8Q37724770-D80601B4-A093-420A-8906-F4559D61E5F4Q41362907-078601EF-5215-43A3-8A66-E5FEE3A66E15Q41880899-15656578-48A9-4C49-B9A0-0F2B16C06A54Q46161762-4B56F87A-D20B-405A-9967-617AB9F71A24
P2860
Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Adverse events in the treatmen ...... from the DOTS-Plus initiative.
@en
Adverse events in the treatmen ...... from the DOTS-Plus initiative.
@nl
type
label
Adverse events in the treatmen ...... from the DOTS-Plus initiative.
@en
Adverse events in the treatmen ...... from the DOTS-Plus initiative.
@nl
prefLabel
Adverse events in the treatmen ...... from the DOTS-Plus initiative.
@en
Adverse events in the treatmen ...... from the DOTS-Plus initiative.
@nl
P2093
P1476
Adverse events in the treatmen ...... from the DOTS-Plus initiative
@en
P2093
A D Pasechnikov
E Jaramillo
E Nathanson
M A Espinal
T E Tupasi
P304
P577
2004-11-01T00:00:00Z